About Dihexa.co.uk

Our Mission

Dihexa.co.uk is dedicated to providing balanced, evidence-based information about Dihexa and related research chemicals to a UK audience. Our mission is to serve researchers, students, and curious individuals by offering accurate, comprehensive resources that explain the science, legal status, and practical considerations surrounding this emerging compound.

We believe that informed decision-making requires access to complete information—including both potential benefits and significant risks. This site presents evidence fairly, acknowledges uncertainty where it exists, and distinguishes carefully between preclinical promise and human clinical reality.

Why This Site Exists

Most online information about Dihexa suffers from critical gaps:

  • Incomplete Narrative: Many sources present only the most promising preclinical findings while ignoring negative results or failed trials
  • Hidden Risks: Potential side effects, contraindications, and limitations of current evidence are often minimised or omitted
  • Unsupported Claims: Exaggerated or speculative claims ("50x more potent than X", "cures Alzheimer's") are presented as fact without scientific basis
  • Regulatory Context Missing: Information about why Dihexa is banned by WADA, why it is not approved by the MHRA, and what these restrictions mean is rarely discussed
  • UK-Specific Gaps: The legal and regulatory landscape differs between countries. Specific UK information is hard to find

Dihexa.co.uk exists to fill these gaps. We provide comprehensive, balanced coverage that helps readers develop genuine understanding rather than uncritical enthusiasm.

Our Editorial Standards

All content on this site adheres to strict editorial principles:

1. Citation and Sourcing

All factual claims are sourced from published research, regulatory documents, or reliable secondary sources. When citing research, we provide context about study design, sample size, and limitations. We do not present anecdotes or unsubstantiated testimonials as evidence.

2. Acknowledgement of Limitations

We clearly state the limitations of current evidence. This includes:

  • Sample sizes in preclinical studies
  • The fact that animal models do not always translate to humans
  • The limited human clinical data available
  • Remaining questions about mechanism, dosage, and long-term effects

3. Preclinical vs. Human Evidence

We use clear language to distinguish between findings from laboratory cells, animal models, and human studies. A promising in vitro result is not the same as evidence that the compound is effective in people. We explicitly avoid collapsing these categories.

4. Balanced Risk Communication

We cover potential risks and side effects with the same rigor we apply to potential benefits. This includes discussing:

  • Adverse events reported in studies
  • Safety concerns raised by regulatory agencies
  • Unknowns about long-term effects
  • Contraindications for certain populations

5. No Promotional Content

This site does not accept advertising, sponsored content, or affiliate arrangements with suppliers. We receive no payment for recommending products or vendors. Our sole aim is to provide independent information.

What We Cover That Others Don't

Dihexa.co.uk is committed to covering aspects of the Dihexa story that are often ignored online:

Retracted Research

Some early Dihexa research has been challenged or retracted. We discuss these controversies transparently rather than pretending they don't exist. Understanding why certain studies were retracted is essential for evaluating the overall evidence base.

The LIFT-AD Failure

The clinical trial of Dihexa in Alzheimer's disease (LIFT-AD) did not meet its primary endpoint. This is the most important human evidence available, and it deserves central focus rather than being buried or spin-doctored. Our research summary examines what LIFT-AD actually showed.

WADA Ban

Dihexa is prohibited by the World Anti-Doping Agency. This reflects significant regulatory concern. We explain why WADA took this action and what it implies about the compound's properties and potential effects.

UK Legal Analysis

Rather than vague statements about "legal status", we provide detailed analysis of how Dihexa fits into UK law, the Psychoactive Substances Act, and the regulatory framework for research chemicals. See our legal status guide for comprehensive coverage.

The Athira Scandal

Athira Pharma, the company developing Dihexa, faced significant controversy regarding data integrity and regulatory compliance. We discuss how these corporate issues affect our confidence in the underlying science.

Medical Disclaimer

Important: This Is Not Medical Advice

Dihexa.co.uk provides information for research and educational purposes only. Nothing on this site constitutes medical advice, and we do not recommend, endorse, or encourage the use of Dihexa or any other research chemical for any purpose.

Dihexa is not approved as a medicine in the UK or most other countries. It has not completed Phase 3 clinical trials. The long-term safety profile in humans is unknown.

If you are considering using any novel compound—whether for research, self-experimentation, or any other reason—you should consult qualified healthcare professionals. They can assess your individual health status, medications, contraindications, and risks.

For the full legal disclaimer, see our Legal Disclaimer page.

Contact & Feedback

We welcome feedback, corrections, and questions from visitors. If you notice inaccuracies, have suggestions for content, or wish to contact us, please use the form below:

Alternatively, you can reach us by email at info@dihexa.co.uk.

Related Pages

For more detailed information, see: